The appearance of Johnson & Johnson’s talquetamab in this year’s Ash press programme will highlight GPRC5D blockade as an important new mechanism in treating multiple myeloma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,